首页 > 市场调查报告书 > 製药

神经疾病

市场调查报告书

商品编码

1708858

全球艾伦·赫恩登-达德利综合征治疗市场（按治疗类型、最终用户和地区划分）

Global Allan-Herndon-Dudley Syndrome Treatment Market, By Treatment Type (Gene Therapy, Hormone Therapy), By End User (Hospital, Specialty Clinics, Others), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)

出版日期: 2025年03月04日 | 出版商:

Coherent Market Insights | 英文 140 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2025 年全球艾伦·赫恩登-达德利症候群治疗市场规模估计为 1,410 万美元，预计到 2032 年将达到 2,080 万美元，2025 年至 2032 年的年复合成长率(CAGR)为 5.7%。

报告范围		报告详细信息
基准年	2024	2025年的市场规模	1410万美元
效能数据	从2020年到2024年	预测期	2025年至2032年
预测期：2025-2032年复合年增长率：	5.70%	2032年价值预测	2080万美元

数字。 2025 年艾伦·赫恩登-达德利综合征治疗的全球市场占有率（按地区）

艾伦·赫恩登-达德利症候群 (AHDS) 是一种由 MCT8 基因突变引起的罕见遗传性疾病。这些突变导致甲状腺激素跨血脑障壁的运输受损。目前，AHDS 的治疗选择有限，且旨在控制症状。首选治疗方法是使用三碘甲状腺原氨酸 (T3) 进行甲状腺荷尔蒙补充疗法。 T3 补充剂有助于恢復大脑中的甲状腺激素水平，改善神经发育和功能。然而，高剂量的 T3 有时会引起震颤、过动和心律不整等副作用。另一种选择是甲状腺素 (T4) 疗法，该疗法依赖细胞内 T4 转化为週边活性形式 T3。这种间接治疗方法效果不佳，因为 MCT8 突变会抑制荷尔蒙的运输和活化。

新兴基因疗法是一种有前景的研究方法，可以直接治疗 AHDS 的潜在遗传原因。在基因治疗中，将 MCT8 基因的健康副本引入患者的细胞或组织中，以取代突变的基因。儘管仍处于研究的早期阶段，但这可以纠正激素运输缺陷，并可能消除终生甲状腺替代的需要。挑战包括开发有效、安全的基因转移载体，以及根据患者特定的 MCT8 突变为其量身定制治疗方案。目前正在进行进一步的研究，以检验基因疗法作为 AHDS 的潜在创新治疗方法。

市场动态：

全球 Allan-Herndon-Dudley 症候群 (AHDS) (MCT8 缺乏症) 治疗市场主要受到 AHDS 盛行率上升的推动，预计这将在预测期内推动市场成长。例如，美国生物技术资讯中心（NCBI）于2020年1月16日发布的数据显示，在约15年的时间内已发现160多名受影响的个体，这表明该综合症可能比以前认为的更为常见。

研究的主要特点

本报告对全球艾伦·赫恩登-达德利综合征 (AHDS) (MCT8 缺乏症) 治疗市场进行了详细分析，并给出了预测期 (2025-2032) 的市场规模和年复合成长率(CAGR)，假设 2024 年为基准年。
它还强调了各个领域的潜在收益成长机会，并说明了该市场的引人注目的投资提案矩阵。
它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景和主要企业采用的竞争策略的重要见解。
全球艾伦·赫恩登-达德利综合征 (AHDS) (MCT8 缺乏症) 治疗市场的主要企业是根据公司亮点、产品系列、关键亮点、业绩和战略等参数列出的。
本报告的见解将使负责人和企业经营团队能够就未来的产品发布、新兴趋势、市场扩张和行销策略做出明智的决策。
全球艾伦·赫恩登-达德利综合征 (AHDS) (MCT8 缺乏症) 治疗市场报告针对该行业的各个相关人员，例如投资者、供应商、产品製造商、经销商、新进入者和金融分析师。
相关人员可以透过用于分析全球 Allan-Heldon-Dudley 症候群 (AHDS) (MCT8 缺乏症) 治疗市场的各种策略矩阵来简化决策。

Report Coverage	Report Details
Base Year:	2024	Market Size in 2025:	USD 14.1 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	5.70%	2032 Value Projection:	USD 20.8 Mn

Allan-Herndon-Dudley syndrome (AHDS) is a rare genetic disorder caused by mutations in the MCT8 gene. These mutations result in impaired thyroid hormone transport across the blood-brain barrier. Current treatment options for AHDS are limited and aim to manage symptoms. The first line of treatment involves thyroid hormone replacement therapy with triiodothyronine (T3). T3 supplements help restore thyroid hormone levels in the brain to improve neurological development and function. However, high T3 doses sometimes cause side effects like tremors, hyperactivity, and irregular heartbeat. The other option is thyroxine (T4) therapy which relies on the peripheral conversion of T4 to active T3 within cells. This indirect method of treatment is not very effective as the MCT8 mutations disrupt hormone transportation and activation.

Emerging gene therapy is a promising investigational approach to directly treat the underlying genetic cause of AHDS. In gene therapy, a normal copy of the MCT8 gene would be delivered into the patient's cells and tissues to replace the mutated one. Though still in early research phase, this could correct the hormone transport defect and eliminate the need for lifelong thyroid supplementation. Challenges include developing effective and safe gene delivery vectors and treatments needing to be tailored to individual patients based on their specific MCT8 mutations. More research is underway to validate gene therapy as an innovative treatment for AHDS in the future.

Market Dynamics:

The global Allan-Herndon-Dudley syndrome (AHDS) (MCT8 deficiency) treatment market is mainly driven by the increasing prevalence of AHDS is expected to propel the market growth over the forecast period. For instance, according to the data published by the National Center for Biotechnology Information (NCBI) in January 16, 2020, the identification of more than 160 affected individuals in approximately 15 years suggests that the syndrome is more common than previously thought.

Key features of the study:

This report provides an in-depth analysis of the global allan-herndon-dudley syndrome (AHDS) (MCT8 deficiency) treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global Allan-Herndon-Dudley syndrome (AHDS) (MCT8 deficiency) treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Rare Thyroid Therapeutics International AB and Erasmus Medical Center
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global Allan-Herndon-Dudley syndrome (AHDS) (MCT8 deficiency) treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Allan-Herndon-Dudley syndrome (AHDS) (MCT8 deficiency) treatment market

Detailed Segmentation:

Global Allan-Herndon-Dudley syndrome (AHDS) (MCT8 deficiency) Treatment Market, By Treatment Type
- Gene Therapy
- Hormone Therapy
Global Allan-Herndon-Dudley syndrome (AHDS) (MCT8 deficiency) Treatment Market, By End User
- Hospital
- Specialty Clinics
- Others (Research institutes, etc.)
Global Allan-Herndon-Dudley syndrome (AHDS) (MCT8 deficiency) Treatment Market, By Region
- North America
- Europe
- Asia Pacific
- Middle East and Africa
- Latin America
Company Profiles
- Rare Thyroid Therapeutics International AB
- Erasmus Medical Center

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Treatment Type
- Market Snippet, By End User
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Increasing prevalence of AHDS
- Increasing Healthcare Expenditure Globally
Key Highlights
Regulatory Scenario
Recent Trends
PEST Analysis
PORTER's Analysis
Mergers, Acquisitions, and Collaborations

4. Global Allan-Herndon-Dudley syndrome (AHDS) (MCT8 deficiency) Treatment Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Global Allan-Herndon-Dudley syndrome (AHDS) (MCT8 deficiency) Treatment Market, By Treatment Type, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Gene Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
Hormone Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

6. Global Allan-Herndon-Dudley syndrome (AHDS) (MCT8 deficiency) Treatment Market, By End User, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospital
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
Others (Research institutes, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

7. Global Allan-Herndon-Dudley syndrome (AHDS) (MCT8 deficiency) Treatment Market, By Region, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Region, 2021 - 2032
- Country Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
  - U.S.
  - Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Region/Country, 2020-2032,(US$ Mn)
North Africa
Central Africa
South Africa

8. Competitive Landscape

Company Profile
- Rare Thyroid Therapeutics International AB
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Erasmus Medical Center
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
Analyst Views

9. Section

References
Research Methodology
About us

02-2729-4219

+886-2-2729-4219

License/价格

全球艾伦·赫恩登-达德利综合征治疗市场（按治疗类型、最终用户和地区划分）